U.S. pharma giant copyright scrapped two experimental weight loss capsules last year—a after-day-to-day capsule, lotiglipron, because of elevated liver enzymes along with a two times-everyday pill, danuglipron, because of robust Unwanted effects—but CEO Albert Bourla has reported the